Replies to post #8963 on Tao Synergies Inc (TAOX)

[runncoach]

You mean the same way that Sigma-1 Pridopidine failed for Teva after early success?

When I look at a potential drug I try to find reasons it might fail, that's why I'm so informed about several of these drugs. It doesn't take long to find S-1 or M-1 problems as research advances.

Or this failure in Japan?
"A Japanese drug company, Toyama Chemical, is developing an Alzheimer's drug with the same sigma-1 receptor mechanism of action as Anavex's Anavex 2-73. Two years ago, Toyama reported results from a randomized, placebo-controlled phase IIa study enrolling 370 Alzheimer's patients.

The results were disappointing: Toyama's drug, T-817MA, failed to demonstrate a statistically significant improvement in memory, cognition or activities of daily living compared to placebo during the 52 weeks of the study."
https://seekingalpha.com/article/4074451-anavex-life-sciences-5-reasons-short?page=3

[runncoach]

Certainly not simple, that's why AVXL failed in combo with another Sig-1 binder donepezil. Failed PR and the only US granted patent AVXL has for 273 for AD that I can see.

https://www.anavex.com/anavex-reports-predicted-clinical-effect-for-anavex-2-73-in-computer-simulation-model-of-alzheimers-disease/

Then in 2016 realized the opposite apparently is in zero clinical trials due to that failed theory.